Myeloprotective effect of high dose medroxyprogesterone acetate on patients receiving cytotoxic chemotherapy

Samur M., Icli F., AKBULUT H., DEMİRKAZIK A., Cay F., Arican A.

Turkish Journal of Cancer, vol.28, no.3, pp.118-123, 1998 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 3
  • Publication Date: 1998
  • Journal Name: Turkish Journal of Cancer
  • Journal Indexes: Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.118-123
  • Keywords: Chemotherapy, Medroxyprogesterone acetate, Myeloprotection
  • Ankara University Affiliated: Yes

Abstract

In the current study, we aimed to evaluate the myeloprotective effect and possible side effects of high dose medroxyprogesterone acetate (HD-MPA) in cancer patients receiving chemotherapy. Twenty-two patients without prior chemotherapy or radiotherapy, who developed grade 2-3 neutropenia following the first cycle of the chemotherapy regimen were entered into the study. Patients were given HD-MPA (1g/day po) during the second course of chemotherapy. The incidence of leukopenia was significantly lower in the second cycle (chemotherapy+HD-MPA). Other hematological parameters showed no significant differences, and HD-MPA was found to be safe with only minor side effects. Moreover, HD-MPA had positive effects on general tolerance to chemotherapy by decreasing anorexia, increasing sense of well being, and improving performance status. In conclusion, HD-MPA was found to be effective in reducing myelotoxic side effects of chemotherapy.